About Genezen - Viral Vector Manufacturer

Founded in 2014, we’re an ambitious viral vector and gene therapy contract development and manufacturing organization (CDMO) with unique historic expertise in viral vector services, specifically lentiviral and retroviral vector manufacturing. Our talented team offers the guidance, technology and manufacturing capacity to help you along your journey to commercializing your innovative therapy.

Scroll Down

Our mission & vision

At Genezen, our mission is simple: to provide quality viral vector services and help deliver life-changing therapies to patients.

We’re an ambitious viral vector CDMO with unique historic expertise in lentiviral and retroviral vector manufacturing.

Meet the people behind the mission statement

Our team is dedicated to getting your viral vector where it needs to go. Communication and collaboration are part of our DNA and we can't wait to talk to you about your current challenges and needs.

Brok Weichbrodt

VP of Operations

Pratima Cherukuri

Chief Scientific Officer

See how we got here

Our Evolution

Founded in 2014 by current Chairman Bill Vincent, our history is packed with innovation and ambition. Following investment by Ampersand Capital Partners’ in 2021, Genezen is catapulted forward built on a foundation of expansive knowledge in lentiviral and retroviral vectors.

Take a look at Genezen's history

See our vacancies

Join the team

We want our employees to be innovative, collaborative problem solvers who are dedicated to meeting the challenges of our clients and a fast-growing market.

Latest news

Find out what's happening right now at Genezen

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more

Genezen Delivers Next Phase of cGMP…

October 3, 2022 – Genezen, a cell and gene therapy Contract...

Read more

How can pseudotyping gammaretrovirus impact manufacturing?

Designing the plasmids that will be transfected into producer cells in...

Read more

Get insights like this directly to your inbox

Sign up to our newsletter